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ABSTRACT
A growing body of research suggests that dopaminergic cell death seen in Parkinson’s
disease is caused by mitochondrial dysfunction. Oxidative stress, with subsequent generation of
reactive oxygen species, is the hallmark biochemical product of mitochondrial dysfunction. The
ketogenic diet has been found to enhance mitochondrial energy production, protect against
reactive oxygen species-generated cell death, and increase adenosine, a purine that modulates
dopamine activity. The current study evaluates the effects of a long-term (5-month) ketogenic
diet on behavioral, neurochemical, and neuroanatomical measures in PINK1-KO rats, a new
animal model of Parkinson’s disease. Both wild-type and PINK1-KO animals fed a ketogenic
diet exhibited significantly higher blood beta-hydroxybutyrate levels. PINK1-KO animals fed a
normal diet experienced a decrease in stride length and an increase in stride frequency over time
which was absent in PINK1-KO animals fed a ketogenic diet. Animals fed the ketogenic diet had
decreased tissue content of both adenosine and inosine in the nucleus accumbens, posterior
caudate, hippocampus, and substantia nigra. Finally, immunohistochemical staining for tyrosine
hydroxylase-positive cells in the substantia nigra suggest a ketogenic diet-induced protection of
dopaminergic cell death. The results of the present study indicate that a long-term ketogenic diet
may positively impact both motor and neuroanatomical correlates and alter neurochemical
systems in a genetic rodent model of Parkinson’s disease.
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INTRODUCTION

Etiology, Symptomology, & Current Treatment
Parkinson’s disease (PD) is a neurological condition which causes motor impairments
such as bradykinesia, muscular rigidity, postural instability, and resting tremors. The National
Institute of Health (NIH) estimates that 500,000 people in the United States suffer from PD;
prevalence of PD is expected to double by the year 2030 as the average age of our population
grows older (NIH, n.d.; Dorsey et al., 2007). PD symptoms have been attributed to the
progressive loss of dopamine (DA) cells in the substantia nigra (SN), but often do not manifest
until 60-70% of these cells are already lost (for review see - Mhyre et al., 2012). These
symptoms do not typically present until later in life with only 10% of diagnoses occurring before
the age of 50 (“Parkinson’s Disease: Hope Through Research,” NIH). According to the NIH, the
average age of symptom onset is 60 while other sources report that the mean age at diagnosis is
70.5 (NIH, n.d.; Van Den Eeden et al., 2003). Furthermore, incidence of PD increases by more
than 350% in people over the age of 50 (Van Den Eeden et al., 2003). The most common
therapy for patients suffering from PD is levodopa (L-DOPA), the precursor to DA, which can
reduce the motor deficits to an extent. Still, treatments which attenuate or prevent dopaminergic
(DAergic) cell death have yet to be discovered.
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Neuroanatomy of PD

Fig. 1 The figure above displays the nigrostriatal pathway in the rat brain, relevant neuronal pathways, and relative
dopamine D2 and adenosine A2A receptor localization in the basal ganglia. Graphic created by Tom Naragon ’17.

The motor deficits associated with PD have been attributed to the loss of DAergic
neurons of the basal ganglia, particularly in the SN (Parkinson, 2002). The basal ganglia include
the dorsal striatum (caudate nucleus and putamen), ventral striatum (nucleus accumbens and
olfactory tubercle), globus pallidus internal and external (GPi and GPe), SN, and the subthalamic
nucleus (STN) (Purves et al., 2001; Fig 2). An expansive discussion of each of these
components is beyond the scope of the current paper but those with direct relevance to motor
function and PD will be discussed. The SN is the main source of DA in the brain and provides
the neurotransmitter to the striatum via the nigrostriatal pathway (Beckstead et al., 1979; Fig
1). The nigrostriatal pathway is the network most affected by Parkinsonian pathology (Dauer
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and Przedborski, 2003). Interestingly, the striatum projects only to other components of the
basal ganglia yet it receives input from a variety of other brain regions; a full anatomical
description is beyond the scope of this thesis.

Fig. 2 The figure above depicts the neuronal pathways of the basal ganglia which play a crucial role in the
facilitation of smooth motor movement in Parkinson’s disease.

In the context of movement, the structures of the basal ganglia play key roles in allowing
the initiation and inhibition of movement (Purves et al., 2001). The thalamus is the main target
for these effects due to thalamocortical projections which facilitate activation of the motor
cortex. The GPi projects GABAergic neurons to the thalamus which inhibit the thalamus from
activating the motor cortex (Purves et al., 2001). When a movement is made, glutamatergic
projections from the motor cortex activate striatal GABAergic neurons. These striatopallidal
GABAergic cells inhibit the GABAergic neurons of the GPi and thus allow for increased
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thalamic activation. The GPe also receives inhibitory input from the striatum and sends its own
GABAergic projections to the STN (Purves et al., 2001). The STN sends excitatory
glutamatergic projections to the SN as well as the GPi. In the SN, glutamatergic neurons
originating from the STN synapse at DAergic neurons which project to the striatum (Purves et
al., 2001). In the GPi, glutamatergic projections from the STN augment firing of GABAergic
projections to the thalamus which reduces thalamocortical facilitation of the motor cortex.
DAergic neurons of the nigrostriatal pathway act on two different dopamine receptors; D1 and
D2. Agonistic action at D1 receptors located on striatopallidal GABAergic neurons augment
inhibition of the GPi. D2 receptors, however, are localized to striatal glutamatergic neurons
which synapse with striatal GABAergic projections to the GPe. Activation of D2 receptors
enhances inhibition of the GPe which sends GABAergic projections to the glutamatergic neurons
of the STN (Purves et al., 2001). It is also important to note the presence of circuitry which
serves as self-modulating feedback inhibition between the SN and the STN via nigral
GABAergic neurons (Purves et al., 2001).
In PD, the death of nigrostriatal DAergic cells would reduce the ability of the GPi to
attenuate excitatory thalamocortical projections. This effect would be compounded by decreases
in the STN’s ability to augment GPi inhibition of thalamocortical projections that would result
from reduction of the SN’s indirect control of the STN by way of the striatopallidal GABAergic
projections to the GPe. Disinhibition of thalamocortical projections to motor areas may explain
the jerky and unwanted movements associated with PD.

Modeling PD
In order to study PD, models that induce the death of nigrostriatal DAergic neurons have
been developed. Several animal models of PD use the administration of toxins specifically
10

designed to produce selective death of DAergic cells. 6-hydroxydopamine (6-OHDA) was one
of the earliest toxin-induced models used to model PD and causes neurotoxicity by generating
oxidative products when it breaks down extracellularly through auto-oxidation (Hanrott et al.,
2006). The reactive oxygen species (ROS) produced cause oxidative stress which has been
observed to lead to mitochondrial dysfunction, nuclear fragmentation, activation of the apoptotic
caspase pathways, and selective DAergic cell death (Hanrott et al., 2006).
Another toxin-induced model was discovered by inhibiting activity of complex I of the
mitochondrial electron transport chain using 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine
(MPTP) and was found to produce selective DAergic cell death (Langston et al., 1983). The
mitochondrial dysfunction created by MPTP leads to the generation of ROS, like in the 6OHDA model, which can result in the activation of programmed cell death (PCD) mechanisms.
Evidence of elevated activation of mitochondrial PCD mechanisms in nigral DAergic cells has
been observed in PD which further strengthens the link between mitochondrial dysfunction and
neurodegeneration in PD (Tatton, 2000; Hartmann et al., 2001). Furthermore, mitochondrial
energy failure has been proposed to disrupt vesicular sequestration of DA (Dauer and
Przedborski, 2003), which results in extravesicular auto-oxidation of DA into DA-quinone,
which reacts with cysteine residues and destroys proteins (Graham, 1978).
These toxin-induced models selectively produce DAergic cell death because these cells
are particularly susceptible to the generation of ROS (Dauer and Przedborski, 2003). This
proclivity for creating ROS is a direct result of enzymatic metabolism of DA, which produces
hydrogen peroxide (H2O2) and superoxide (O2-) radical, and auto-oxidation of cytosolic DA
(Graham, 1978).
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The major drawback to acute toxin-induced models of PD is that they do not accurately
mimic the progressive loss of nigrostriatal DAergic neurons associated with human
manifestations of the disease. However, a recent genetic model developed by Sage Laboratories
has been able to address this challenge. By inhibiting the synthesis of phosphatase and tensin
(PTEN)-induced kinase 1 (PINK1) the PINK1-knockout (PINK1-KO) model induces
mitochondrial dysfunction and progressive loss of DAergic cells in the SN (Villeneuve et al.,
2014). In healthy cells, decreases in mitochondrial membrane potential trigger the accumulation
of PINK1 on the outer mitochondrial membrane (Imai, 2012). PINK1 recruits another protein,
Parkin, from the cytosol which triggers the degradation and clearance of the damaged
mitochondria. Without PINK1, dysfunctional mitochondria are not disposed of and produce
toxic levels of ROS. Furthermore, it has been reported that PINK1-KO rats display hind limb
dragging associated with their mutation (Dave et al., 2014). The PINK1-KO model presents a
unique opportunity to study the progressive loss of DAergic neurons and observe Parkinson’slike motor deficits. Again, mitochondrial dysfunction is a well-established means for inducing
DAergic cell death, making the PINK1-KO a useful model of human PD.

Purine Involvement in PD
While L-DOPA may be the most common treatment for PD, its long-term use has
frequently been associated with decreased efficacy (“off” periods) and dyskinesias (Ahlskog and
Muenter, 2001). As a result, the need for non-dopaminergic (non-DAergic) therapies to address
PD symptoms is necessary.
Several members of the purine neurochemical family like guanosine and uric acid have
been linked to PD. Recent in vitro work has revealed that guanosine is able to activate cell
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survival pathways in the presence of 6-OHDA (Giuliani et al., 2014). A large body of literature
has been published which points to uric acid as a potential biomarker for disease progression in
PD (Cipriani et al., 2010; Gao et al., 2016). Uric acid has also been shown to be neuroprotective
against the free radical peroxynitrite, which has been associated with the pathology of several
inflammatory CNS diseases (Scott and Hooper, 2001). Additionally, reduced levels of uric acid
have been reported in postmortem SN tissue (Church and Ward, 1994). The most prominent
findings however, are those concerning the purine adenosine. The neuroprotective properties of
adenosine are well studied. Although adenosine A1 receptors are not directly linked to PD
pathology, they are widely expressed throughout the CNS in glia and neurons (Dixon et al.,
1996). A1 receptors can exert neuroprotective effects by reducing the influx of presynaptic
calcium and inhibiting glutamate release (Masino et al., 2002). Further research has indicated
that this effect may in fact be one of feedback inhibition of hyper-excitatory firing, which may
otherwise deplete energy and result in neural death (Lovatt et al., 2012).
A large body of research has revealed significant expression of adenosine A2A receptors
in the basal ganglia (Rivkees et al., 1995; Rosin et al., 1998; Hettinger et al., 2001; Rebola et al.,
2005; Morelli et al., 2010). In striatopallidal neurons, activation of A2A receptors increases the
secretion of GABA in the globus pallidus (Ochi et al., 2000). Excess GABA in the globus
pallidus suppresses the firing of pallidal GABAergic projections to the STN. A reduction in the
inhibitory action of these projections leads to increased activation of glutamatergic neurons in
the STN, which form synapses in both the globus pallidus and the SN. In a slightly more
macroscopic perspective, highly active GABAergic projections of the basal ganglia attenuate
the thalamocortical impact on the motor cortex and, ultimately, reduce the ability to elicit
smooth motor function, as seen in patients with PD (Hauser RA and Schwarzschild MA, 2005).
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In light of the localization and function of A2A receptors, the purinergic neurochemical
system represents a unique non-dopaminergic target for modulating the striatal signaling altered
in PD. Numerous studies have explored the effects of antagonistic action at A2A receptors in
animal models of PD. A 1974 paper induced a unilateral lesion of the nigrostriatal DA pathway
using 6-hydroxydopamine (6-OHDA) (Fuxe and Ungerstedt, 1974). Fuxe and Ungerstedt
(1974) found that 6-OHDA-lesioned rats treated with L-DOPA displayed significant
improvements in turning behavior following application of the A2A antagonists theophyllamine
and caffeine. Later studies confirmed this finding using other A2A antagonists such as 7-(2phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH
58261), (E)-8-(3,4-Dimethoxystyryl)-1,3-diethyl-7-methylxanthine, 8-[(1E)-2-(3,4Dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione (KW-6002
or istradefylline), and (E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)vinyl]-7 -methyl2,6-dioxo-1-prop-2-ynyl-1,2,6,7-tetrahydropurin-3-yl]propyl] (MSX-3), all of which improved
turning behavior in animals treated with L-DOPA or DA receptor agonists (Fenu et al., 1997;
Koga et al., 2000; Strömberg et al., 2000a; Pinna et al., 2016). Furthermore, repeated treatment
with A2A antagonists failed to exhibit any reduced efficacy of motor stimulation suggesting that,
A2A antagonism ameliorates tolerance issues associated with L-DOPA treatments alone (Pinna et
al., 2001).
Antagonism of the A2A receptor has also been studied in the MPTP model of PD. It is
important to note that rodent models are more resistant to this toxin and most successful
reproduction of Parkinsonian syndrome with MPTP has been achieved in non-human primates
(Bové et al., 2005). Since translation to non-human primates is an essential step in proof-ofconcept for A2A receptor antagonism in human PD, studies have used monkeys treated with
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MPTP to test the efficacy of targeting A2A receptors (Kanda et al., 2000). The A2A antagonist
KW-6002 significantly improved motor dysfunction induced by MPTP toxicity (Kanda et al.,
2000).
Recently, a dual target therapy combining antagonists of the metabotropic glutamate
receptor 5 (mGluR5) and the adenosine A2A receptor was tested in rats treated with 6-OHDA
(Fuzzati-Armentero et al., 2015). While a combination of the mGluR5 antagonist, 2-methyl-6(phenylethynyl) pyridine (MPEP), and the A2A antagonist, MSX-3, better protected DA cells in
the SN from toxin-induced death, the MSX-3 alone also significantly reduced the toxin-induced
cell death in the SN (Fuzzati-Armentero et al., 2015). Behaviorally, MSX-3 administered alone
was found to significantly potentiate L-DOPA-induced turning behavior. Again, combination
of MSX-3 with MPEP increased this effect and required lower concentrations than individual
administration (Fuzzati-Armentero et al., 2015). Another recent study combined an A2A
antagonist with a serotonin 1A/1B receptor agonist (Pinna et al., 2016). Pinna and colleagues
found that in MPTP-treated monkeys the combination of both drugs reduced the dose of LDOPA necessary for therapeutic effects. Additionally, administration of all three drugs
significantly prevented dyskinetic-like behavior (Pinna et al., 2016). Still, antagonists of the A2A
receptor are the frontrunners in non-dopaminergic therapies for PD with the first adenosine A2A
antagonist, istradefylline, being recently approved in Japan after successful phase-3 trials
(Kondo and Mizuno, 2015).

Purines and the Ketogenic Diet
The ketogenic diet (KD) is a high fat, low carbohydrate eating regimen and is already
well established as a successful alternative treatment for medically refractory epilepsy (Freeman
and Vining, 1998; Hemingway et al., 2001). The calorie restriction of the KD induces a state of
15

ketosis by breaking down fatty acids to ketone bodies in the liver (Paoli et al., 2013). These
ketone bodies replace glucose as the body’s main driver of energy production and have been
shown to result in enhanced production of energy substrates (DeVivo et al., 1978). More
specifically, elevated fatty acid levels by a KD eventually reach a threshold which surpasses the
capacity of the tricarboxylic acid (TCA) cycle and leads to enzymatic conversion of acetyl-CoAs
into acetoacetate (ACA) and 𝛃-hydroxybutyrate (𝛃HB). Both ACA and 𝛃HB are ketone bodies
which travel through the blood, cross the blood-brain barrier, and enter the cells of the central
nervous system. These ketone bodies are then transported into mitochondria where they are
converted into acetyl-CoA and subsequently into ATP via the Krebs cycle (Masino and Rho,
2012). As an energy substrate ketone bodies have been found to improve ATP production and
protect against ROS-induced damage (Kashiwaya et al., 2000; Kim et al., 2007; Maalouf et al.,
2007; Veech, 2014).
The past decade has seen major strides in discovering the underlying processes which
explain the KD’s efficacy in epilepsy. Currently, the most compelling theory points to inhibitory
action at adenosine A1 receptors (Masino et al., 2011). As such, research has pressed on,
investigating the purinergic system’s role in the anticonvulsant effects of the diet. One
hypothesis proposes that the KD may in fact be increasing ATP levels which may be rapidly
broken down into adenosine in the extracellular space (Masino and Geiger, 2008). By
mimicking the low glucose environment of a KD, a study conducted by Kawamura et al. (2010)
showed that reduction of extracellular glucose results in the release of ATP via pannexin-1
hemichannels in hippocampal CA3 pyramidal neurons. Dephosphorylation of this extracellular
ATP yields adenosine, which acts on A1 receptors coupled to ATP-sensitive K+ channels to
reduce neuronal excitability (Kawamura et al., 2010).
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In addition to its application in epilepsy, the diet has also been proposed to have
therapeutic benefits in other neurological conditions in which deficits in mitochondrial energy
metabolism play a role (Baranano and Hartman, 2008; Stafstrom and Rho, 2012). The
profundity of the KD’s effects on mitochondrial energy metabolism was demonstrated by work
using microarrays, which revealed an upregulation of 34 transcripts encoding energy metabolism
enzymes (Bough et al., 2006). Furthermore, increased mitochondrial profiles were observed in
hippocampal slices of these KD-fed rats. Stimulation of synaptic transmission in these slices
exhibited high resistance to a low glucose environment, which suggests an increase in energy
reserves (Bough et al., 2006).
While glucose restriction and ketone body-driven energy metabolism enhances
production of energy substrates, ketone bodies specifically have been reported to have
neuroprotective properties. ACA and 𝛃HB are both able to decrease the mitochondrial output of
destructive ROS by increasing NADH oxidation in the mitochondrial respiratory chain (Maalouf
et al., 2007). The same study found that glutathione, an endogenous free radical, was also
reduced. This may be explained by a study which reported that elevated glutathione peroxidase
activity was observed in the hippocampus of rats fed a KD (Ziegler et al., 2003). Ketone bodies
also reduce mitochondrial membrane permeability induced by oxidative stressors such as, H2O2
and diamide (Kim et al., 2007). The same study affirmed the ability of ketone bodies to decrease
ROS levels and provides substantial evidence of their capacity to prevent mitochondrial
permeability and oxidative damage in neurons.

The Metabolic Theory: Potential Effects of a Ketogenic Diet on PD
It is well documented that the DAergic neurodegeneration seen in PD is the result of
mitochondrial dysfunction (Parker et al., 1989; Schapira et al., 1990; Hattori et al., 1991; Perier
17

et al., 2012). This is supported by studies which report that DAergic neurons are highly sensitive
to free radicals, which are natural byproducts of energy metabolism (Miyazaki and Asanuma,
2008). The KD has been shown to improve mitochondrial energy production and the ketone
body 𝛃HB is a more efficient energy substrate in terms of ATP generation (DeVivo et al., 1978;
Veech, 2014). In light of the growing body of research highlighting the role of mitochondrial
dysfunction in PD, as well as literature which reports KD-induced enhancements in
mitochondrial energy production, the KD could present a possible therapeutic benefit for PD.
The purpose of the current study is to evaluate the KD’s ability to attenuate the
progressive cell death seen in PINK1-KO rats. This model presents a unique opportunity to
target progressive loss of DAergic neurons, test the therapeutic efficacy of KD-driven
improvements in mitochondrial function, and measure the KD’s impact on Parkinsonian motor
deficits. Behavioral data on gait alterations of the animals was recorded using the DigiGait
motorized treadmill system. Staining for tyrosine hydroxylase (TH) will be conducted on nigral
tissue to assess DAergic cell death. A reverse-phase high performance liquid chromatography
(HPLC) system will be used to quantify purine levels in 7 discrete brain regions. Blood testing
for glucose and 𝛃HB will be used to establish each animal’s level of ketosis. It was
hypothesized that the KD would enhance mitochondrial energy metabolism such that an
attenuation in DAergic cell death would be observed in the KD-fed PINK1-KO rats. It was
expected that PINK1-KO rats on the normal diet (ND) would exhibit increased gait
abnormalities compared to KD-fed PINK1-KO rats, and in control rats fed either diet.
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MATERIALS AND METHODS
Chemicals
Adenosine, guanosine, inosine, xanthine, hypoxanthine, guanine, uric acid, sodium
chloride, potassium phosphate monobasic, and sodium 1-pentane sulfonate were acquired from
Sigma Aldrich (St. Louis, MO, USA). Potassium phosphate monobasic, HPLC-grade
acetonitrile, and 85% phosphoric acid were acquired from ThermoFisher Scientific (Waltham,
MA, USA). Potassium chloride, and sodium phosphate dibasic heptahydrate were acquired
from J.T. Baker Analytical (Center Valley, PA, USA).

Animal Handling and Diet Administration
All animal care, use, and surgical procedures were approved by the Institutional Animal
Care, the Use Committee of Trinity College, and are in accordance with the National Institutes of
Health Guide for the Care and Use of Laboratory Animals. A total of 24 PINK1 +/+ and -/- rats
from SAGE Laboratories (St. Louis, MO, USA) were housed in pairs in plastic cages with
stainless steel tops and were exposed to a standard 12hr light: 12hr dark cycle. Temperature and
humidity were kept constant electronically and food and water were provided ad libitum, KD
was changed daily. All animals received the control diet until 3 months of age at which point
KD and control groups were established. The KD used was the AIN-76A Modified diet which is
8.6% protein, 75.1% fat, 3.2% carbohydrate and contains added mineral and vitamin mixes
(BioServ, Flemington, NJ, USA). Rats were given a 5-day acclimation period upon arrival
before they were weighed for the first time. Weight gain was continuously monitored every 2
weeks. Once during each of the 3 months prior to sacrifice, blood levels of 𝛃HB and glucose
were tested using ketone and glucose test strips and digital meters (Abbott Inc., Alameda, CA,

19

USA). At 8 months old animals were deeply anesthetized using isoflurane (Henry Schein
Animal Health, Dublin, OH, USA) before and during sacrifices. Animals were perfused using 1x
phosphate buffered saline (PBS) solution (for details see appendix A). The brain of each animal
was rapidly harvested and stored in a solution of dry ice and ethanol until tissue was processed
approximately 1 hour after sacrifice.

DigiGait Behavioral Analysis
Animals undergoing gait analysis were put on a motorized treadmill tilted at a 13° angle
and walked downhill at a speed of 18 cm/s. Video footage was recorded from beneath the
treadmill and the area of advancing and retreating paws was analyzed using the DigiGait
software. These data were used to evaluate balance, coordination, and gait abnormalities.

Tissue Processing
Brains were sectioned on a Leica SM 2000 R Microtome stage controlled by a Physitemp
BFS-3TC temperature regulator set to -20°C (Physitemp Instruments, Clifton, NJ). Brain slices
were taken coronally at 1.5mm thickness and bilateral tissue punches were taken from the
following regions: motor cortex (MC), somatosensory cortex (SC), nucleus accumbens (NA),
anterior caudate (AC), posterior caudate (PC), hippocampus (HC), and substantia nigra (SN) (Fig
3). See appendix B for detailed procedures and protocols.
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Fig. 3 The above figure depicts the slices and punch site locations of the following brain regions: motor cortex
(MC), somatosensory cortex (SC), nucleus accumbens (NA), anterior caudate (AC), posterior caudate (PC),
hippocampus (HC), and substantia nigra (SN).

Rat brain regions were identified using a rat stereotaxic atlas (Pellegrino et al., 1979).
Tissue punches were transferred to labeled microcentrifuge tubes containing 400µL ethanol and
sonicated using the Tekmar Sonic Disruptor. Samples were centrifuged for 30 min at 12,400
rpm using the Fisher Scientific Microcentrifuge 235c at 4°C. Supernatants were transferred to
separate microcentrifuge tubes and rotovapped at 45°C for 30 min. The amount of protein in
each tissue punch was evaluated using standard Modified Lowry Protein Assay protocol from the
protein pellets left in the original centrifuge tubes. Neurotransmitter pellets were resuspended in
1mL of DiH2O and 7µL of an 8µg/L DHBA solution was added as an internal standard. Fully
processed samples were stored at -80°C until analyzed by HPLC.
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HPLC Analysis
Purines were quantified using a modified version of a previously described method
(Burdett et al., 2013). Two mobile phases were used for reverse-phase HPLC analysis. Mobile
phase A (MP-A) contained 0.52 mM sodium 1-pentane sulfonate, 0.20 M potassium phosphate
monobasic and was pH adjusted to 3.5 using 85% phosphoric acid (Baker Analyzed;
Phillipsburg, NJ, USA). Mobile phase B (MP-B) contained identical concentrations as MP-A
plus an addition of 10% acetonitrile (HPLC-Grade, Fisher Scientific, Pittsburgh, PA, USA).
The gradient parameters were as follows: 0-6 min of 100% MP-A, 6-15.5 min ramp to
45% A - 55% B (Fig 4). This gradient was held until 20 min and was followed by a 15 min
equilibration period during which the system was rinsed with 100% MP-A before the next
injection was made (Fig 4).
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Fig. 4 The figure above is a graphical representation of the mobile phase (MP) gradient parameters used for reversephase high performance liquid chromatography (HPLC) analysis of purine levels. Mobile phase A (MP-A) was a
0.52 mM sodium 1-pentane sulfonate, 0.20 M potassium phosphate monobasic solution and was pH adjusted to 3.5
using 85% phosphoric acid. Mobile phase B (MP-B) was created from MP-A but was 10% acetonitrile.
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A Hitachi L 2130 HPLC pump was used at a flow rate of 0.7mL/min and separation was
carried out at 22°C on a 150 x 3.00mm LUNA 5µm C18 analytical column (Phenomenex,
Torrence, CA, USA). A sample volume of 100µL was manually injected into the HPLC system.
Dual electrochemical detection (ESA Coulochem III; E1 = -0.15V; E2 = +0.70V; Thermo
Scientific, Sunnyvale, CA, USA) and UV detection (λ1 = 254nm; BioAnalytical Systems, West
Lafayette, IN, USA) were used to quantify purine levels. Chromatographic data was collected,
stored, and analyzed using EZ Chrom chromatography software (Thermo Scientific).

TH-Staining
The Vectastain® ABC Kit (Vector Labs, Burlingame, CA, USA), and anti-TH antibody
(Santa Cruz Biotechnology, Dallas, TX, USA) were used for immunohistochemical staining (for
details see appendix C).

Protein Assays
Protein assays were conducted using the standard Modified Lowry Protein assay method
(for details see appendix C).

Data Collection, Quantification, and Analysis
Calibration standards were run prior to brain sample injections and a standard calibration
curve was used to quantify purine levels in the brain regions of interest. Data was compiled
using Excel files and statistically analyzed using GraphPad Prism version 6.0 (GraphPad
Software, Inc., San Diego, CA, USA). Statistical significance between groups was determined
by two-way ANOVA with post-hoc comparisons.
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Experimental Groups
A total of 24 Long-Evans Hooded rats, 12 wild-type (WT) and 12 PINK1-KO (KO), were
included in the study. Animals arrived in groups of 4, 2 WT and 2 KO, on a monthly basis and
were assigned letters A-X for identification. 4 study groups of 6 animals each were established
as follows: WT fed a normal diet (WT/ND), WT fed a ketogenic diet (WT/KD), KO fed a
normal diet (KO/ND), and KO fed a ketogenic diet (KO/KD). One animal from the KO/KD
group died prematurely due to an unforeseen hypersensitivity to isoflurane anesthetic
administered when trimming toenails prior to DigiGait behavioral testing. The use of isoflurane
for toenail trimming was discontinued immediately and no other animals were lost prematurely
for any reason.
Brains from one animal from each study group, 4 brains total, were sent to the University
of Hartford in order to conduct TH-staining of the SN to assess DAergic cell death.
A gravity-driven perfusion apparatus was used during surgical dissection of animals.
Initially, an 8L container was filled with 1x PBS and placed on a shelf approximately 2 feet
above animals during dissection. Animals ‘C’ and ‘D’, from the KO/ND group, were not
successfully perfused and cerebral blood could be observed following dissection. Furthermore,
lesions were observed in the following animals: D, F, H, I, L, and K. Animals D, F, and H
exhibited either asymmetrically enlarged or exploded ventricles which were attributed to the
excessive flow rate of the gravity-driven perfusion apparatus. Rats I-X did not show
asymmetrically enlarged or exploded ventricles, likely due to the decrease in volume of 1x PBS
in the perfusion container after perfusions were conducted for rats A-H. Available images of the
observed lesions can be found in appendix D. Final calculations of purine levels in rats A-H in
all brain regions were, in most cases, more that 250% higher than those in rats I-X. This
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disparity is likely due to perfusion-induced dispersion of purines away from their regions of
origin and, as such, data from animals A-H were excluded from neurochemical analysis. At this
point each study group consisted of 3 animals.
Finally, two samples for neurochemical analysis by HPLC were inadvertently lost during
the tissue sample preparation process. The posterior caudate tissue from animal ‘R’ came loose
in the microcentrifuge. Tissue from the substantia nigra of rat ‘V’ was not collected after
excessive slicing of brain tissue caused the region to be missed entirely.
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RESULTS

Chronic KD does not prevent weight gain
A 5-month chronic KD did not prevent weight gain in either the WT or KO animals (Fig
5). Unpaired t-tests showed no significant differences (for all comparisons p>0.05) in starting
weight between any of the study groups (WT/ND: 334g ± 11.88, n = 6; WT/KD: 374g ± 25.19, n
= 6, t = 1.57; KO/ND: 366g ± 9.39, n = 6, t = 3.32; KO/KD: 362g ± 11.75, n = 5, t = 2.36).
Unpaired t-tests also showed no significant differences in final weight between any of the study
groups (WT/ND: 518g ± 21.55, n = 6; WT/KD: 593g ± 48.20, n = 6, t = 1.55; KO/ND: 575g ±
15.60, n = 6, t = 3.65; KO/KD: 536g ± 54.62, n = 5, t = 0.34). Furthermore, after 5 months on
the KD, both WT and KO animals were overtly indistinguishable from normal diet-fed animals.
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Fig. 5 Chronic KD does not prevent weight gain in wild-type (WT) and knock-out (KO) animals fed a normal diet
(ND) or ketogenic diet (KD). A) KO/KD animals (n = 5) B) KO/ND animals (n = 6) C) WT/KD animals (n = 6) D)
or WT/ND animals (n = 6).

KD alters 𝛃HB but not glucose levels
Animal age at the time of blood tests did not have any affect on the results of either 𝛃HB
or glucose testing (F = 0.51, DFn = 2, p>0.05 and F = 1.30, DFn = 2, p>0.05, respectively). Data
from all three months were then combined to compare the effect of the KD on blood 𝛃HB and
glucose levels. As seen in figure 6, animals fed the KD showed increased blood 𝛃HB levels
when compared to animals fed a normal diet. WT animals on the KD showed an increase of
157% over WT animals on the normal diet (0.94 mmol/L ± 0.05, n = 15 vs. 0.60 mmol/L ± 0.04,
n = 13, p<0.05). PINK1-KO animals fed a KD showed an increase of 167% in blood 𝛃HB when
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compared to KO animals on the normal diet (0.97 mmol/L ± 0.06, n = 12 vs. 0.58 mmol/L ±
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0.05, n = 13, p<0.01). Blood glucose levels were not affected by the KD (Fig 7).

Fig. 6 Blood beta-hydroxybutyrate (𝛃HB) levels in wild-type (WT) and knock-out (KO) animals fed a normal diet
(ND) or ketogenic diet (KD). The WT/KD group had significantly higher 𝛃HB than WT/ND (* p<0.05). KO/KD
animals had significantly higher 𝛃HB than KO/ND groups (** p<0.01). Data from months 6, 7, and 8 were
combined and compared by study group (n = 12-15 data points per group).
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Fig. 7 Blood glucose levels in wild-type (WT) and knock-out (KO) animals fed a normal diet (ND) or ketogenic diet
(KD). No significant differences were seen between any of the experimental groups. Data from months 6, 7, and 8
were combined and compared by study group (n = 12-15 data points per group).

KD increases stride length and decreases stride frequency
At 3 months of age there was no statistically significant difference in stride length or
stride frequency between any of the experimental groups (Fig 8a and 10a). At 8 months, KO
animals on the normal diet showed significantly shorter stride length than WT animals on the
normal diet (8.33 cm ± 0.05, n = 6 vs. 10.55 cm ± 0.05, n = 2, p<0.05) and WTs on the KD
(12.21 cm ± 0.40, n = 8, p<0.01; Fig 8b). Interestingly, KD-fed wild type animals had longer
stride length than normal diet-fed WTs (12.21 cm ± 0.40, n = 8 vs. 10.55 cm ± 0.05, n = 2,
p<0.01) at 8 months. Figure 9 shows that the stride length of the KO/ND animals gradually
decreased over time, ultimately showing a 16.5% decrease from 3 month values, whereas all
other groups remained equal to or greater than their respective 3 month values.
No significant differences in stride frequency were seen between any of the groups at 3
months (Fig 10a). However, at 8 months KO animals fed a normal diet showed a significant
increase in stride frequency (2.18 steps/s ± 0.17, n = 6) compared to WT animals fed a normal
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diet (1.7 steps/s ± 0.0, n = 2, p<0.05) or KD (1.49 steps/s ± 0.05, n = 8, p<0.01; Fig 10b). KDfed WT animals showed significantly lower stride frequency than normal diet-fed WTs (1.49
steps/s ± 0.05, n = 2, p<0.01). Overtime, stride frequency of the KO animals fed a normal diet
increased by 18% over the 3 month value (Fig 11).
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Fig. 8 Effects of the ketogenic diet (KD) on stride length in wild-type (WT) and knock-out (KO) animals fed a
normal diet (ND) or KD. A) 3 months B) and 8 months. KO/ND animals showed a significant reduction in stride
length at 8 months compared to WT animals on the ND (* p<0.05). WT/KD animals had significantly higher stride
length than KO/ND animals at 8 months (** p<0.01). For all experimental groups n = 2-4.
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Fig. 9 Changes in stride length in wild-type (WT) and knock-out (KO) animals fed a normal diet (ND) or ketogenic
diet (KD). KO/ND animals showed a decrease in stride length at 8 months compared to 3 months. KO/KD animals
showed a similar stride length at 3 and 8 months. For all experimental groups n = 2-4.
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Fig. 10 Effects of the ketogenic diet (KD) on stride frequency in wild-type (WT) and knock-out (KO) animals fed a
normal diet (ND) or KD. A) 3 months B) and 8 months. KO/ND animals showed a significant increase in stride
frequency at 8 months compared to WT animals fed a ND (* p<0.05). WT/KD animals had significantly lower stride
frequency than the WT/ND group at 8 months (** p<0.01). For all experimental groups n = 2-4.
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Fig. 11 Changes in stride frequency between 3 and 8 months in wild-type (WT) and knock-out (KO) animals fed a
normal diet (ND) or ketogenic diet (KD). Stride frequency of KO/ND animals increased at 8 months compared to 3
months. KO/KD animals showed a similar stride frequency at 3 and 8 months. For all experimental groups n = 2-4.

KD changes purine neurochemistry
The KD selectively reduced adenosine and inosine levels in the brains of both WT and
KO animals (Fig 12 and 13). In the nucleus accumbens, adenosine was 57% lower in KD-fed
animals compared to WT animals fed a normal diet (WT/KD: 0.94 µg/mg protein ± 0.20, n = 3;
KO/KD: 0.94 µg/mg protein ± 0.17, n = 3 vs. WT/ND: 2.18 µg/mg protein ± 0.29, n = 3, p<0.05;
Fig 12a). In the posterior caudate adenosine was 60% lower in the KD-fed WTs and 57% lower
in the KD-fed KOs compared to normal diet-fed WT animals (WT/KD: 0.99 µg/mg protein ±
0.31, n = 3; KO/KD: 1.04 µg/mg protein ± 0.10, n = 3 vs. WT/ND: 2.45 µg/mg protein ± 0.42, n
= 2, p<0.01 and p<0.05; Fig 12b).
Inosine, a metabolite of adenosine, was non-significantly reduced in the nucleus
accumbens of KD-fed WT animals and significantly reduced in the KD-fed KOs compared to the
normal diet-fed WT animals (KO/KD: 0.42 µg/mg protein ± 0.02, n = 3 vs. WT/ND: 0.81 µg/mg
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protein ± 0.04, n = 3, p<0.05; Fig 13a). In the hippocampus, KD-fed WT and KD-fed KO
animals had significantly lower inosine levels (42% and 43%, respectively) than those of KOs
fed a normal diet (WT/KD: 0.60 µg/mg protein ± 0.10, n = 3; KO/KD: 0.59 µg/mg protein ±
0.11, n = 3 vs. KO/ND: 1.03 µg/mg protein ± 0.23, n = 3, p<0.05; Fig 13b). Finally, in the
substantia nigra, KD-fed KOs showed significantly less inosine (36%) than normal diet-fed WT
animals (KO/KD: 0.74 µg/mg protein ± 0.15, n = 3 vs. WT/ND: 1.16 µg/mg protein ± 0.15, n =
3, p<0.05; Fig 13c).
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Fig. 12 Adenosine levels in in wild-type (WT) and knock-out (KO) animals fed a normal diet (ND) or ketogenic diet
(KD) A) nucleus accumbens B) and the posterior caudate. Both KD-fed groups showed significantly lower
adenosine levels in the nucleus accumbens (A) compared to the WT/ND group (# p<0.05). The WT/KD and
KO/KD groups also showed significantly lower adenosine levels in the posterior caudate (B) compared to WT/ND
animals (## p<0.01 and # p<0.05, respectively). For all study groups n = 2-3.
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Fig. 13 Inosine levels in wild-type (WT) and knock-out (KO) animals fed a normal diet (ND) or ketogenic diet
(KD). A) nucleus accumbens B) hippocampus C) and the substantia nigra. KO/KD animals showed significantly
lower inosine levels than WT/ND animals in both the nucleus accumbens (A) and substantia nigra (C) (# p<0.05).
KD-fed WT and KO animals showed significantly less inosine in the hippocampus (B) than KO/ND animals (#
p<0.05). For all study groups n = 2-3.

KD appears to protect nigral dopamine cells
Immunohistochemical staining for TH-positive cells in the SN revealed that a KO animal
fed a normal diet had noticeably fewer dopamine cells than a WT animal fed the KD (Fig 14).
The KD appeared to prevent this nigral TH-positive cell loss in KO animals.
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Fig. 14 Tyrosine hydroxylase (TH)-positive cells in the substantia nigra of a wild-type (WT) and knock-out (KO)
animal fed a normal diet (ND) or ketogenic diet (KD). A KO animal fed the ND had observably less TH-positive
cells in the substantia nigra than either KD-fed animals. For all groups n = 1.
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DISCUSSION

Chronic KD does not prevent weight gain
The present study found that rats fed the KD for 5 months gained weight similarly to rats
fed a normal diet. Several interesting differences between the weights of KD- and ND-fed
animals were observed. Weight gain plots of KD-fed animals were more spread out than those
of ND-fed animals. At the end of the 5-month diet, the final weights of KO/KD and WT/KD
animals had standard deviations of 122g and 118g compared to 38g and 52g in KO/ND and
WT/ND, respectively. Taken together, these data suggest that there may be greater weight-gain
variability in KD-fed animals than in ND-fed animals.
A large number of studies on the effects of prolonged KD in animal models have
examined KD regimens persisting for up to 11 weeks (DeVivo et al., 1978; Al-Mudallal et al.,
1995, 1996; Hori et al., 1997; Cheng et al., 2009; Ruskin et al., 2013; Church et al., 2014).
Administration of a KD for 20 days in Sprague-Dawley rats did not result in as much variance as
we observed following a 5-month KD (DeVivo et al., 1978). Greater weight gain in KD-fed
animals compared to control-fed animals has been reported after a slightly longer (5 week) KD
regimen, although this difference was not statistically significant (Hori et al., 1997). Interesting
results from a 5-6 week KD study, which used slightly higher protein content (10.4%) than the
present study, described that animals were restricted to 10g of the diet per day in order to avoid
excessive weight gain (Al-Mudallal et al., 1996). In comparison, our KD was only 8.6% protein
and while the KD patties provided to our animals were observably equivalent in size they were
not weighed. During daily replacement of KD patties, complete consumption of the previous
day’s patty was never observed.
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KD alters 𝛃HB but not glucose levels
Since animals on the KD were not provided any external sources of carbohydrates,
tolerated the diet, and gained weight it was deduced that they were converting fatty acids to
ketone bodies to serve as their primary energy substrate. 𝛃HB and glucose blood levels were
measured as an indicator of the conversion to ketosis. KD-fed KO animals had significantly
higher blood 𝛃HB levels than their ND-fed counterparts. Interestingly, no significant differences
in blood glucose levels were seen between either genotype or diet group. Other research reports
elevated blood and cerebral 𝛃HB levels in KD-fed versus control-fed animals with no change in
blood or cerebral glucose levels (Al-Mudallal et al., 1995). Under normal conditions, rat blood
𝛃HB levels have been reported to be between 0.20 – 0.30 mmol/L and glucose levels are
between 4.00 - 12.17 mmol/L (Leino et al., 2001; Veech, 2004; Paoli et al., 2011). At 8 months
of age, normal diet-fed WT animals had mean 𝛃HB and glucose levels of 0.60 and 4.86 mmol/L,
respectively. KO animals fed the normal diet showed similar 𝛃HB levels (0.58 mmol/L) but
slightly higher blood glucose levels (6.07 mmol/L) at 8 months. While 𝛃HB levels in our normal
diet fed animals appear to be slightly higher than previous reports, blood glucose levels were
well within the range reported by previous studies. After a 35-day KD, Leino et al. (2001)
reported that rat plasma 𝛃HB and glucose levels were 1.0 and 11.5 mmol/L, respectively. In
comparison, our KD-fed WT and KO animals had 𝛃HB levels of 0.94 and 0.97 mmol/L and
glucose levels of 6.46 and 6.08 mmol/L, respectively. While 𝛃HB levels reported in the current
study are nearly identical to previous reports, glucose levels in KD-fed animals are much lower.
This could be a result of a shift in energy substrate from glucose to ketone bodies but, since
blood data was only collected during the final three months and no initial level prior to KD
administration was established no firm conclusion could be drawn regarding a change in energy
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substrate. Still, the fact that no significant differences in blood glucose levels were observed
between KD- and ND-fed groups suggests that perhaps a 5-month KD provides animals with
ample time to compensate for the KD-induced glucose shortage. Indeed, it has been reported
that glucose levels in KD-fed animals do not significantly differ from pre-diet levels after a 1month KD regimen (Leino et al., 2001).
The neuroprotective properties of 𝛃HB are well established in Parkinsonian models. In
an MPTP mouse model of PD, infusion of 𝛃HB protected against both the degeneration of
DAergic neurons and the motor deficits associated with the MPTP toxin (Tieu et al., 2003).
𝛃HB has also been found to reduce the production of free radicals that induce lipid peroxidation
of cell membrane and cause cell death (Maalouf et al., 2007).
Reports suggest that between 50% and 80% of Parkinson’s patients have an atypical
glucose tolerance (Lipman et al., 1974; Sandyk, 1993). This impaired glucose intolerance is a
hyperglycemic state which often precedes diabetes. Furthermore, many of these glucose
intolerant patients with PD fulfill criteria for diabetes (Lipman et al., 1974). Glucose
consumption leads to insulin secretion and catecholamines have been suggested as modulators of
this process (Buse et al., 1970). This glucose intolerance is made worse by L-DOPA therapies
and it has been proposed that diabetes in Parkinson’s disease may increase the severity if motor
dysfunction (Sandyk, 1993). Individuals with glucose intolerance can exhibit fasting glucose
levels that can be slightly elevated which may explain the slightly higher levels levels observed
in our KD-fed animals compared to those fed the normal diet (American Diabetes Association,
2005).
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KD increases stride length and decreases stride frequency
In humans, PD progression is associated with a decrease in stride length and shuffling
gait (Morris et al., 1994). While patients are often able to compensate for these changes when
walking at a pace of their selection, gait hypokinesia becomes apparent when walking speed is
kept constant (Morris et al., 1994). Our data on PINK1-KO-induced gait changes align with
these findings in humans as stride length in KO/ND animals was over 20% shorter than WT/ND
animals at 8 months. In contrast, KO/KD animals were observed to have a mean stride length
that was only 6% shorter than WT/ND animals. Interestingly, WT animals fed the KD exhibited
a 16% increase in stride length between 3 and 8 months. Research examining the effects of the
KD on the R6/2 1J mouse model of Huntington’s disease, which found evidence of KD-induced
improvements in locomotor coordination in male mice (Ruskin et al., 2011). Our results indicate
that KD-fed KO animals had similar stride length at both 3 and 8 months while KO animals fed
the normal diet exhibited a steady decrease in stride length representing a loss of 16.5% over the
course of the experiment.
In parallel with a decrease in stride length, KO/ND animals showed a significant increase
in stride frequency at 8 months of age compared to WT/ND animals at the same time point. This
change in KO/ND animals amounted to a 15% increase over time, whereas KO/KD animals
exhibited nearly identical stride frequency at both 3 and 8 months. WT/KD animals exhibited a
15% reduction in stride frequency between 3 and 8 months of age. As one might expect, the
relationship between stride length and stride frequency is approximately inversely proportional.
Taken together these results suggest a KD-induced attenuation of PINK1-KO-induced motor
deficits.
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Hind limb dragging has been reported in 30% of PINK1-KO rats (Dave et al., 2014).
Three of the 12 KO animals in the current study were observed to exhibit hind limb dragging, a
25% prevalence rate. All three of these animals were fed the ND which may suggest that the KD
prevented the development of this impairment. The DigiGait video footage captured hind limb
dragging from below these animals while they walked and allowed for interesting observations
to be made. In all three hind limb draggers an equinovarus-like folding of the toes under the pad
of the dragged paw was observed. The current study is the first to report this feature of the hind
limb dragging in PINK1-KO animals. Our initial results suggest that the KD prevented the
development of Parkinson’s-like gait changes in PINK1-KO animals.

KD changes purine neurochemistry
The KD is well known for its anti-epileptic effects (Hori et al., 1997; Dahlin et al., 2005,
2012; Baranano and Hartman, 2008; Masino et al., 2012). It has been suggested that a KDinduced increase in extracellular adenosine acts on A1 receptors which reduce neuronal
excitability (Masino and Geiger, 2008; Masino et al., 2011, 2012). Furthermore, adenosine is
well-known for its modulatory influence over dopaminergic transmission in the basal ganglia via
A2A receptors (Hettinger et al., 2001; Rebola et al., 2005; Morelli et al., 2010, 2012).
Antagonism of A2A receptors on nigrostriatal DAergic neurons leads to an augmentation of
inhibitory GABAergic activity, enhanced regulation of thalamocortical-facilitated motor
function, and makes smooth motor movements possible (Ochi et al., 2000; Hauser RA and
Schwarzschild MA, 2005). In light of the modulatory role of adenosinergic A2A receptors on
DAergic transmission and smooth motor movement, research has focused on targeting A2A
receptors for potential therapeutic applications in PD (Pinna et al., 1996, 2001, 2016; Fenu et al.,
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1997; Koga et al., 2000; Strömberg et al., 2000b). This extensive support of A2A receptor
antagonism in PD contributed to the recent approval of istradefylline, an A2A antagonist, as an
additional therapy for PD (Kondo and Mizuno, 2015).
In the current study, a 5-month KD appeared to have a depressive effect on purine levels
in both KO and WT animals. In the nucleus accumbens adenosine levels fell by 57% in both
WT and KO animals fed a KD compared to WT animals fed a normal diet. In comparison
KO/ND animals exhibited only a 30% decrease in adenosine in the nucleus accumbens compared
to WT/ND animals. Additionally, adenosine was lower in the posterior caudate of KD-fed WT
and KO animals by 60% and 58%, respectively, compared to WT/ND animals; a 26% decrease
was observed in KO/ND animals. A similar trend was seen with inosine, a downstream
metabolite of adenosine. In the nucleus accumbens KD-fed WT and KO animals had 46% and
48% less inosine, respectively, than WT/ND animals while KO/ND animals showed only a 30%
decrease. In the hippocampus KO/ND animals showed a 19% increase in inosine compared to
WT/ND animals while KD-fed WT and KO animals were observed to have decreases of 28%
and 29%, respectively. The substantia nigra also showed a depression of inosine levels by 36%
in both KD-fed groups and 15% in KO animals fed a normal diet. One potential explanation for
these decreases could be that, due to the prolonged length of the diet, compensatory mechanisms
become hyperactive and reduce purine levels.
Precise quantification of purines in the brain is very difficult because even the slightest
ischemic event can lead to rapid degradation of ATP and subsequent increase in adenosine levels
(Delaney and Geiger, 1996). In order to obtain precise cerebral purine levels it is important to
inactivate the enzymes involved in the purine metabolic pathway. One such method uses highenergy focused microwave systems which not only kill experimental animals but simultaneously
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denature proteins and halt enzyme function (Delaney and Geiger, 1996). This microwave
method has been compared to more traditional decapitation methods and found significant
differences in adenosine content in regions evaluated in the present study (Delaney and Geiger,
1996). Using 10kW microwave irradiation adenosine levels in the cortex, striatum, and
hippocampus were between 50 and 75 times lower than those of animals sacrificed using
decapitation. In comparison, adenosine levels in the cortex of animals sacrificed by decapitation
were 0.022 µg/mg protein versus 3.46 µg/mg protein (combined motor and somatosensory cortex
values) detected in our study. Our adenosine levels may be higher due to the perfusion
procedure conducted on all animals prior to decapitation. Clearance of blood in the brain creates
the kind of ischemic environment which leads to massive increases in adenosine up to 100-fold
(Chu et al., 2013).

KD appears to protect nigral dopamine cells
Immunohistochemical staining for DA cells in the SN showed that a KD-fed KO animal
had nearly 150% more DA neurons than a KO animal fed a normal diet. Previous studies have
also reported the KD’s protection of nigral DAergic neurons in toxin-induced models of PD
(Cheng et al., 2009; Yang and Cheng, 2010). Studies evaluating the PINK1-KO confirm that
KO animals do, in fact, exhibit nigral DA cell depletion (Dave et al., 2014; Villeneuve et al.,
2014). Due to our small sample size, only one animal from each study group was stained for
TH-positive cells and, as such, the present findings require additional animals to determine the
statistical power of the observed effects. Still, cell counts from representative images of three of
the four study groups (WT/ND group not shown due to technical difficulties in staining
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procedure) suggest that the KD is able to prevent DAergic cell death in the PINK1-KO model of
PD.

Methodological Considerations
As discussed previously (see methods), unforeseen errors in the perfusion of 8 animals
led to removal of 3 rats from each group for purine quantification by HPLC. Additionally, the
method of sacrifice likely resulted in inflated adenosine levels. In the event of a follow-up study
the following recommendations are proposed:
•

That a pressure-driven, rather than gravity-driven perfusion apparatus be used to perfuse
cerebral vasculature

•

Animals from each study group be sacrificed using microwave irradiation, rather than
perfusion and decapitation, for quantification of purines by HPLC

•

That a greater number of animals be included in the study

Conclusions
This study reports that a 5-month KD exhibits therapeutic potential to ameliorate gait
changes and DAergic cell death induced by the PINK1-KO. Furthermore, neurochemical
analysis suggests that a prolonged KD may have a depressive effect on purines in discreet
regions of the striatum, basal ganglia, and the hippocampus. The findings of the current thesis
provide initial evidence of the beneficial effects of the KD in the PINK1-KO model of PD and
are deserving of a follow-up study with a larger sample size to reaffirm these promising results.
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APPENDIX – A. Solution Preparation

3x PBS (1L):
24.0g NaCl
8.01g Na2HPO4 •7H2O
0.6g KCl
0.74g KH2PO4
The above solutes were dissolved in 1L of DiH2O and pH adjusted to 7.45 using 10M NaOH.
The solution was then vacuum filtered.
Note: 1x PBS used for animal perfusion was created by diluting 300mL of 3x PBS to
900mL using DiH2O.

Stock Purine Megamix (PurM):
10µg of the following chemicals were dissolved in 100mL of DiH2O: Adenosine, guanosine,
inosine, xanthine, hypoxanthine, guanine, and uric acid.

Stock DHBA Internal Standard Solution (DISS):
Two concentration levels of DISS were used for different groups of animals over the course of
the study (see appendix C for details).
8µg/mL DISS was created by diluting 4µg of DHBA to 500mL using DiH2O.
16µg/mL DISS was created by diluting 8µg of DHBA to 500mL using DiH2O.
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Preparation of Mobile Phase (MP) Solutions:
MP-A (1L)
0.1g sodium 1-pentane sulfonate
27.2g potassium phosphate monobasic
The quantities of the two solutes above were dissolved in 1L with DiH2O, pH adjusted to
3.5 using 85% phosphoric acid, vacuum filtered for HPLC, then degassed for 45 min.
MP-B (250mL)
25mL of HPLC-grade acetonitrile was diluted to 250mL using MP-A and degassed for
15-20min.
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APPENDIX – B. Pre-surgical Data Collection and Surgical Procedure

DigiGait Behavioral Testing:
Rats were placed on the DigiGait automated treadmill at a decline of 13 degrees and a
treadmill speed of 18cm/s. Rats from each study group were selected for behavioral testing
based on their initial willingness to walk. Representatives from each study group were
established and tested once every month starting at 3 months old. During testing, rats that
were reluctant to walk were placed in a ‘redo’ category and tested again at the end of the
session.

Blood Testing for 𝛃HB and Glucose:
Blood tests were conducted three times, once during each of the last three months before
sacrifice, by the tail prick method. Ketone and glucose levels were measured using 𝛃HB and
glucose test strips and digital meters.

Surgical Procedure:
Scrubs, lab coats, facemasks, protective eyewear, and gloves were worn at all times during
surgeries. Approximately 4-5mL of isoflurane liquid anesthetic was added to an isolation
chamber located in a fume hood. Animals were placed in the chamber until signs of
consciousness were no longer observed. To ensure that the animal was deeply anesthetized a
sharp foot pinch was administered. A nose cap containing a cotton ball and approximately
1mL of isoflurane was used intermittently during surgery to ensure that animals remained
fully anesthetized. An incision below the ribcage was made so that the heart was exposed. A
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sharp 18-guage needle was placed in the left ventricle of the heart and valve of the gravitydriven 1x PBS perfusion apparatus was opened. A small incision in the right atrium was
made to allow efflux of blood. Perfusions were allowed to continue until fixation tremors
were observed. At this point, the sharp-tipped needle was replaced with a dull-tipped needle
which was reinserted into the left ventricle (Note: rats A-D were not perfused with the dulltipped needle, nor was the sharp-tipped needle position adjusted during perfusion). To
ensure a complete perfusion of the cerebral vasculature the dull-tipped needle was positioned
in the ascending aorta. The perfusion was continued until all of the following signs were
observed: fluid exiting the incision in the right atrium was clear (no blood), heart and liver
were observed to show significantly reduced blood content (less red, more pale/pink in
color), and fixation tremors ceased. Animals were then decapitated and brains were rapidly
dissected and placed in a solution of ethanol and dry ice.
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APPENDIX – C. Post-surgical Tissue Processing and Data Collection Procedures

Brain Slicing, Tissue Punching, and Brain Sample Preparation:
1. Microtome was cooled to -20 C using Physitemp regulator. The blade was cooled with
dry ice
2. Brains were mounted using freezing medium and oriented with frontal regions facing
upward.
3. Five 1.5mm slices were taken in order to take tissue punches from the following regions:
Slice 1: Motor cortex
Slice 2: Nucleus accumbens, somatosensory cortex, and anterior caudate
Slice 3: Posterior caudate
Slice 4: Hippocampus
Slice 5: Substantia nigra
4. Bilateral punches were taken from the regions described above, placed in blue 1.5mL
centrifuge tubes containing 400uL HPLC-grade ethanol, and sonicated using the Tekmar
pestle sonicator until tissue was thoroughly broken up.
5. Samples were then spun down at 2400rpm for 30 min in a microcentrifuge stored in -4 C.
6. After 30 min, the supernatant was carefully removed and transferred to yellow 1.5mL
microcentrifuge tubes. (Note: blue microcentrifuge tubes were stored in a -80 C freezer
for protein assays).
7. The ethanol in the supernatant was evaporated in the rotovap at 45 C for 30 min.
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For Rats A-H:
8. The neurotransmitter pellet remaining in the yellow tubes were resuspended in 1mL of a
0.1µg/mL solution of DHBA in DiH2O.
For Rats I-L:
8. 7µL of an 8µg/mL DHBA solution was added to 500µL of DiH2O and neurotransmitter
pellet.
For Rats M-X:
8. 7µL of a 16.6µg/mL DHBA solution was added to 500µL of DiH2O and neurotransmitter
pellet.
9. All brain samples were stored in a -80 C freezer until analyzed by HPLC.

HPLC Analysis:
A 100µL sample loop attached to a manual injector was used for sample injections. Prior to
running calibration standards or brain samples, an injection of DiH2O was run with the dual
MP gradient protocol to establish an acceptable baseline. In a random ordered, each of the
five calibration standards was injected and a calibration curve was generated for each of the 7
purine analytes (Note: detection of guanine and uric acid was not consistent and, as such,
analysis of these two compounds could not be included in the study). Calibration standards
were prepared as follows:
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Preparation of Purine Calibration Standards:
Standard
Concentration
0.01µg
0.05µg
0.1µg
0.5µg
1.0µg

Volume of DISS

Volume of PurM

Volume of DiH2O

25µL
25µL
25µL
25µL
25µL

2 µL
10 µL
20 µL
100 µL
200 µL

1973 µL
1965 µL
1955 µL
1875 µL
1775 µL

Once a full set of calibration standards had been run and calibration curves generated, brain
samples were run. On days following the injection of all five calibration standards the typical
injection order was as follows:
DiH2O
Calibration Std
3-4 Brain Samples
Calibration Std
3-4 Brain Samples
Calibration Std
Between each injection, the injection syringe and sample loop were rinsed first with a 50/50
Methanol/DiH2O solution, then with 100% DiH2O.

Protein Assays:
Standards:
1) Created 1N Folin Reagent by diluting 2N Folin & Ciocalteau Reagent by half using
DiH2O
2) Protein standards were created in 2mL microcentrifuge tubes as follows:
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Std #

µL DiH2O

µL Albumin
Protein (mg)
Protein
0
500
0
0
1
480
20
0.04
2
470
30
0.06
3
460
40
0.08
4
450
50
0.10
5
430
70
0.14
3) 500µL of Modified Lowry Protein Assay Reagent (MLPAR) was added to each standard,
mixed, and allowed to react for 10 min.
4) After 10 min 100µL of 1N Folin reagent was added to each standard, mixed, and allowed
to react for 30 min.
5) Absorbance of each standard was measured at 750nm
For Brain Samples:
1) 500µL of DiH2O was added to each protein sample, then sonicated to mix
2) 500µL of MLPAR was added to each sample, mixed, and allowed to react for 10 min.
3) After 10 min 100µL 1N Folin reagent was added to each sample, mixed, and allowed to
react for 30 min.
4) Absorbance at 750nm was measured for each sample.

TH-Staining Procedure:
Four rats (one from each study group) were perfused using 4% paraformaldehyde and
post-fixed in 4% paraformaldehyde until they could be sliced. Full brains were placed in a
sucrose gradient solution 30% sucrose and PBS for 24 hours, then transferred to 20% sucrose for
24 hours, and finally to a 10% solution for 24 hours. Brains were then frozen in a slurry of dry
ice and 2-methyl butane for 4-8 min. Stored at -80 C for 24 hours. Defrosted in a -20 C freezer
prior to slicing. Slices 20 microns thick of the substantia nigra were taken using a Cryocut 1800
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set to 22 C and placed on Superfrost (ThermoFisher brand) slides. Slides were stored at -20 C
until staining procedure was carried out. Slices were then fixed with acetone pre-cooled to -20 C.
Once acetone had evaporated sections were washed twice in 1x PBS for 5 minutes. Slides were
then incubated in 0.3% H2O2 in a 5% solution of goat serum in 1x PBS for 10 min to quench
peroxidase enzyme activity. After 10 min, slides were rinsed with DiH2O for 3 min. Slides were
then washed again using 1x PBS for 5 min. Slides were then incubated for 30 min with diluted
normal blocking serum 1x PBS and goat serum. After 30 min, excess serum was blotted from
slides. Slides were then incubated overnight in 1:500 ratio of anti-TH to 1x PBS and goat serum
solution of primary anti-TH antibody diluted using 1x PBS and 5% serum. Slides were then
placed in a makeshift humidity chamber with a wet paper towel to keep slides moist. Parafin
covers were then placed on each slide and left for overnight (ideally left for 10 hours). The
following day paraffin covers were removed slides were washed 3 times for 10 min with 1x PBS.
Sections were then incubated for 30 min with 1:200 solution of biotinylated secondary antibody
diluted using PBS serum. After 30 min slides were washed with 1x PBS for 5 min, then
incubated for 30 min with Vectastain ABC reagent. After 30 min slides were washed in 1x PBS
for 5 min, then 100µL of 3,3’-diaminobenzidine (DAB) substrate working solution was applied
for 2-10 min (until color of staining was revealed). Once color of stains appeared, slides were
placed in 1x PBS to stop the reaction. 1x PBS was then blotted from slides and 100µL of
glycerol was carefully applied to the coverslips before placing the coverslips on the slides.
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APPENDIX – D. Supplementary Data

Table 1. Summary of purine neurochemistry by brain region1 in ketogenic diet (KD)- and normal
diet (ND)-fed PINK1-KO (KO) and wild-type (WT) animals2

Adenosine
WT/ND
WT/KD
KO/ND
KO/KD
Guanosine
WT/ND
WT/KD
KO/ND
KO/KD
Inosine
WT/ND
WT/KD
KO/ND
KO/KD
Xanthine
WT/ND
WT/KD
KO/ND
KO/KD

MC

SC

NA

AC

PC

HC

SN

2.17
±0.59
0.78
±0.28
2.21
±0.99
1.20
±0.15

1.29
±0.11
0.89
±0.45
1.38
±0.47
1.06
±0.11

2.18
±0.29
0.67
±0.36
1.43 ±
0.28
0.94
±0.17

1.35
±0.38
0.90
±0.44
1.47
±0.17
1.29
±0.03

2.45
±0.42
0.78
±0.45
1.58
±0.25
1.04
±0.10

1.45
±0.13
0.85
±0.43
1.31
±0.32
1.02
±0.04

0.80
±0.06
0.41
±0.37
2.88
±1.36
0.50
±0.05

0.07
±0.02
0.31
±0.22
1.10
±0.73
0.08
±0.02

0.13
±0.04
0.21
±0.14
1.05
±0.49
0.08
±0.03

0.11
±0.03
0.17
±0.10
1.10
±0.48
0.06
±0.02

0.07
±0.02
0.18
±0.08
1.04
±0.49
0.09
±0.03

0.12
±0.05
0.19
±0.10
1.17
±0.59
0.04
±0.02

0.07
±0.03
0.28
±0.12
1.29
±0.71
0.08
±0.04

0.05
±0.01
0.35
±0.22
0.50
±0.29
0.07
±0.00

0.66
±0.08
0.38
±0.08
0.23
±0.13
0.36
±0.06

0.60
±0.03
0.38
±0.16
0.28
±0.23
0.42
±0.07

0.81
±0.04
0.35
±0.12
0.31
±0.26
0.42
±0.02

0.63
±0.10
0.30
±0.13
0.13
±0.11
0.39
±0.04

0.59
±0.15
0.34
±0.13
0.26
±0.15
0.34
±0.06

0.83
±0.21
0.47
±0.20
0.54
±0.47
0.59
±0.11

1.16
±0.15
0.47
±0.44
0.46
±0.36
0.74
±0.15

0.09
±0.02
1.11
±1.04
0.46
±0.17
0.16
±0.07

0.08
±0.03
0.43
±0.37
0.35
±0.12
0.10
±0.05

0.11
±0.01
0.77
±0.67
0.34
±0.11
0.08
±0.03

0.11
±0.02
0.43
±0.35
0.34
±0.12
0.08
±0.02

0.12
±0.01
0.51
±0.42
0.32
±0.14
0.06
±0.01

0.08
±0.01
0.63
±0.53
0.56
±0.26
0.07
±0.02

0.07
±0.01
0.68
±0.60
0.61
±0.29
0.05
±0.01
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Hypoxanthine
WT/ND

2.39
1.97
2.06
1.89
2.16
1.64
2.28
±0.45
±0.58
±0.33
±0.21
±0.25
±0.24
±0.44
WT/KD
2.01
1.38
1.35
1.27
1.36
1.60
1.41
±0.60
±0.14
±0.10
±0.12
±0.09
±0.12
±0.14
KO/ND
0.86
0.73
0.74
0.72
0.81
0.53
0.65
±0.77
±0.66
±0.66
±0.67
±0.69
±0.45
±0.58
KO/KD
1.52
1.52
1.30
1.31
1.27
1.56
1.49
±0.07
±0.16
±0.06
±0.18
±0.04
±0.19
±0.09
1
MC – motor cortex; SC – somatosensory cortex; NA – nucleus accumbens; AC – anterior
caudate; PC – posterior caudate; HC – hippocampus; SN – substantia nigra
2

Values given in µg/mg protein ± SEM

Images of Various Lesions and Ventricular Abnormalities

Image 1 Rat D incomplete perfusion of cerebral vasculature and third ventricle asymmetry in posterior caudate (PC)
slice.

Image 2 Rat D incomplete perfusion of cerebral vasculature and lateral lesion of caudate observed in hippocampal
(HC) slice.
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Image 3 Rat F lesion and perfusion-induced ventricular asymmetry.

Image 4 Rat H perfusion-induced asymmetrical third ventricle in posterior caudate (PC) slice.

Image 5 Rat H perfusion-induced exploded left third ventricle in hippocampal (HC) slice.

65

Image 6 Rat L lesion first observed in motor cortex (MC) slice.

Image 7 Rat L lesion continued into posterior caudate (PC) slice.

Image 8 Rat L lesion started to close up after posterior caudate (PC) slice.
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Image 9 Rat K lesion in right dorsal accumbal tissue.
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APPENDIX – E. Manuscript from related undergraduate work
The following is a manuscript submitted for publication. It represents my undergraduate work
which used the same HPLC method for quantifying purines as the current thesis to examine how
the KD affects this neurochemical system.

The ketogenic diet does not alter tissue purine levels in mouse brain
Jacob G. Rubin,§ and William H. Church*, Ŧ

§ Neuroscience Program, Trinity College, 300 Summit Street, Hartford, CT, 06106, USA
Ŧ Department of Chemistry and Neuroscience Program, Faculty of Chemistry and Neuroscience, Trinity College,
300 Summit Street, Hartford, CT, 06106, USA

Highlights
•

3-week ketogenic diet did not alter tissue purine levels in wild-type mice

•

Control-fed mice showed negative correlation between dopamine activity and adenosine
levels in the cortex

•

Ketogenic-fed mice did not exhibit negative correlation between dopamine activity and
adenosine levels in the cortex

Abstract
Adenosine has been implicated in the therapeutic effect of the ketogenic diet. It is also known to
modulate dopaminergic activity. We previously showed that the ketogenic diet increased
cortical dopamine activity. This study evaluated whether the ketogenic diet produced changes in
brain adenosine levels and purine activity. Samples from the previous study were analyzed for
purines using a high performance liquid chromatography method for the quantification of
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adenosine, hypoxanthine, xanthine, and inosine. No alteration in tissue levels of purinergic
compounds was found in the ketogenic diet treatment group when compared to the control diet
group. A negative correlation between dopaminergic activity and adenosine tissue levels was
found in the cortex of the control diet group but was absent in samples from the ketogenic diet
group. These findings support previous literature regarding interaction between the
dopaminergic and purinergic neuronal systems and suggest a possible ketogenic diet-induced
change in the purinergic modulation of cortical dopaminergic activity in mice.

Keywords: Adenosine; Ketogenic Diet; Dopamine; Purines; Epilepsy

1. Introduction
Epilepsy is a neurological disorder associated with episodic seizures, sensory disturbances,
loss of consciousness, and unusual behavior. The ketogenic diet (KD) has successfully been
used to treat medically refractory epilepsy, especially in children (Sirven et al., 1999;
Hemingway et al., 2001). The diet consists of a high fat, low protein, and low carbohydrate
regimen that produces a change in metabolism such that blood glucose levels decrease and ßhydroxybutyrate levels increase (Hartman et al., 2007). Currently the mechanisms through
which the KD ameliorates epileptic seizures is poorly understood.
Studies examining the neurochemical changes associated with the KD have been limited to
date. The KD has previously been reported to affect glutamatergic systems (Yudkoff et al., 2004;
Dahlin et al., 2005), adenosine (Masino et al., 2011; Ruskin and Masino, 2012) and
catecholamine transmitters, including dopamine (DA) (Szot et al., 2001; Weinshenker, 2008;
Dahlin et al., 2012). Increased levels of the tryptophan metabolite kynurenic acid in the striatum
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and hippocampus, but not the cortex, have also been observed in rats fed a KD (Żarnowski et al.,
2011). Previous work in our lab found that mice fed a chronic (three-week) KD had increased
DAergic activity in the motor and somatosensory cortices (Church et al., 2014).
The KD has been found to improve mitochondrial function and thus energy metabolism
(Stafstrom and Rho, 2012). It has been suggested that metabolic changes induced by the KD
impact purine neurochemistry. Kawamura et al. (Kawamura et al., 2010) showed that reducing
extracellular glucose causes the neuronal release of ATP. Zhang et al. (Zhang et al., 1995) found
that stimulation of P2Y receptors, by ATP, resulted in increased extracellular DA in the rat
striatum. Adenosine, the breakdown product of extracellular ATP, also has the ability to
modulate DAergic activity (Krügel et al., 2003; Fuxe et al., 2007). Alteration of adenosine levels
has been suggested to be associated with the anti-seizure effects of the KD (Masino and Geiger,
2008; Greene, 2011). Taken together, these findings suggest a potential change in the interaction
between adenosine and DAergic activity under the metabolic state induced by the KD.
The purpose of the present work was to determine if the KD (1) altered adenosine levels in
brain tissue and (2) altered the activity of the purinergic system. We analyzed samples from six
brain regions in mice fed a KD for three weeks for adenosine and its metabolites. While no
change in tissue levels of purines was found, we observed that a negative correlation between
cortical DA activity and adenosine levels in control diet mice was absent in KD mice.

2. Materials & Methods
2.1. General overview, and animals
The brain samples were obtained from the study by Church et al. (Church et al., 2014).
The current study evaluated the neurochemical concentrations of adenosine (Ado), inosine (Ino),
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xanthine (Xanth), and hypoxanthine (Hypo). Purine content was measured in the motor cortex
(MC), somatosensory cortex (SC), nucleus accumbens (NA), anterior and posterior caudateputamen (ACP and PCP), and the midbrain (MB) using high performance liquid chromatography
(HPLC) with UV and electrochemical detection (Burdett et al., 2013). All animal care, use, and
surgical procedures were approved by the Institutional Animal Care, the Use Committee of
Trinity College, and are in accordance with the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
2.2. Chemicals
Two mobile phases were used for HPLC analysis. Mobile phase A (MP-A) contained
0.52 mM sodium 1-pentane sulfonate, 0.20 M potassium phosphate monobasic and was pH
adjusted to 3.5 using 85% phosphoric acid (Baker Analyzed; Phillipsburg, NJ, USA). Mobile
phase B (MP-B) contained identical concentrations as MP-A plus an addition of 10% acetonitrile
(HPLC-Grade, Fisher Scientific, Pittsburgh, PA, USA). All purine chemicals used as standards
were acquired from Sigma Aldrich (St. Louis, MO, USA).
2.3. HPLC Parameters
The neuroactive compounds were separated using a dual-gradient reverse-phase HPLC
system with electrochemical (EC) and UV detection. The mobile phases were run at a flow rate
of 0.5mL/min. Separation was carried out at 22°C on a 150 x 2.00mm LUNA 5µm C18
analytical column (Phenomenex, Torrence, CA, USA) using a dual mobile phase gradient to
achieve proper separation of the analytes. The gradient was 100% MP-A for 6 minutes
increasing to 55% MP-B at 14 minutes. The 45% MP-A and 55% MP-B gradient was
maintained from 14 – 18 minutes then returned to 100% MP-A. Total separation time was 20
minutes and the system was allowed to equilibrate for 15 min between each sample injection.
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The sample injection volume was 100µL. Dual electrochemical detection (ESA Coulochem III;
E1 = -150mV; E2 = +500mV; Thermo Scientific, Sunnyvale, CA, USA) and UV detection (λ1 =
254nm; BioAnalytical Systems, West Lafayette, IN, USA) were used to quantify the purines.
Chromatographic data was collected, stored, and analyzed using EZ Chrom chromatography
software (Thermo Scientific).
2.4. Statistical Analysis
Differences in the levels of purines in the brain tissue were evaluated using two-way
ANOVA with post hoc comparisons (Bonferroni; n = 6-7 brains per diet group; GraphPad Prism
6.0, GraphPad Software, Inc., San Diego, CA, USA).

3. Results & Discussion
Table 1. Purine tissue content from selected brain regions of mice fed either a normal chow (Control) or
a ketogenic diet (KD) for three weeks.a
Brain
Region

Hypoxanthine
Control

Xanthine

Inosine

Adenosine

KD

Control

KD

Control

KD

Control

KD

79.6 ± 7.7

2.5 ± 0.4

3.4 ± 1.1

29.9 ± 10.3

24.7 ± 5.4

71.8 ± 25.5

50.4 ± 6.6

90.1 ± 6.5

1.7 ± 0.3

3.6 ± 1.0

19.5 ± 6.4

26.7 ± 4.7

54.4 ± 19.8

49.2 ± 7.2

61.1 ± 13.1

8.5 ± 4.9

4.0 ± 2.3

29.2 ± 9.9

30.2 ± 7.1

40.2 ± 12.3

42.9 ±11.6

48.8 ± 9.5

6.5 ± 2.9

1.7 ± 0.7

48.4 ± 19.5

15.8 ± 2.6

71.2 ± 32.4

34.6 ± 7.3

51.6 ± 7.4

6.2 ± 2.4

2.6 ± 1.3

16.7 ± 5.2

20.9 ± 3.5

40.8 ± 13.0

31.1 ± 3.2

44.8 ± 15.4

4.2 ± 2.4

1.8 ± 0.5

42.0 ± 9.7

34.5 ± 13.1

23.1 ± 7.2

13.9 ± 4.0

132.9 ±
MC

40.7
102.8 ±

SC

23.3
78.3 ±

NA

18.9
155.1 ±

ACP

88.8
42.2 ±

PCP

18.9
111.9 ±

MB
a

37.4

Data are reported as ug/mg protein ± S.E.M. for n = 6 and 7 KD and control, respectively
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3.1. A ketogenic diet does not alter tissue purine levels in mice
A three-week KD regimen did not alter endogenous purine levels in any of the brain
regions analyzed (Table 1). Figure 1 shows that a KD had no effect on adenosine activity in the
regions analyzed. The mechanism by which the KD ameliorates seizures in animals and humans
is not known. Numerous neurochemical systems have been implicated with recent studies
focusing on energy metabolism and adenosine(Greene, 2011; Ruskin and Masino, 2012).
Previously it has been reported that transgenic mice with spontaneous hippocampal seizures
experienced decreased seizure frequency following a KD. After being fed a three-week KD
these transgenic mice were reported to have low endogenous adenosine levels due to an
overexpression of adenosine kinase (Fedele et al., 2005). After being fed a three-week KD,
seizure frequency decreased by almost 90% but could be restored by injecting exogenous
glucose or adenosine A1 receptor antagonists (Masino et al., 2011). The current findings indicate
that the KD did not alter endogenous purine levels in wild-type (WT) mice (Table 1). Although
not statistically significant, KD-fed mice were observed to have lower adenosine levels than
control-fed mice across almost all the brain regions analyzed. This finding is consistent with a
recent paper which reported that non-disease-state mice fed a KD show lower levels of adenosine
in the hippocampus than controls (Lusardi et al., 2015). However, this may not be reflective of
diet-induced changes in neuronal purinergic activity. One measure frequently used to evaluate
neuronal activity is to compare the levels of metabolites to the parent compound (Heffner et al.,
1980; Kato et al., 1984; Church et al., 1986; Desole et al., 1996). We subsequently evaluated
adenosine activity (Fig 1) and saw no alteration as a result of the KD. These findings do not
support an enhanced augmentation of adenosine as a possible anti-seizure mechanism for the
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KD. However, the methods used in this study measure both intra- and extracellular purine
levels. It is possible that the KD alters mechanisms exclusively impacting extracellular levels of
adenosine that would not be observable under the present experimental conditions. Additionally,
the contribution of purines from residual blood found in post-mortem brain tissue could be a
confounding factor. This is currently under investigation.

Hypo+Ino+Xanth/Ado

25

Control
KD

20
15
10
5

M
B

PC
P

AC
P

NA

SC

M
C

0

Brain Region
Figure 1. Effect of the KD on adenosine activity. Adenosine activity was defined as the sum of adenosine
metabolite levels (hypoxanthine, xanthine, and inosine) divided by adenosine levels. No significant differences in
the ratio of adenosine metabolites to adenosine were detected; (p>0.05), Control n = 7, KD n = 6.

3.2. The KD alters the relationship between purinergic and dopaminergic systems
Since adenosine has a main role in the CNS as a modulator of DA activity, we were
interested to see if the KD altered the relationship between DA activity and adenosine levels.
Previous research from this lab has shown that the KD increases DA activity exclusively in the
motor and somatosensory cortices (Church et al., 2014). Figure 2 reports the correlation between
DAergic activity and adenosine in brain samples of both cortical regions. A negative correlation
was observed in animals fed the control diet (r=-0.88, p<0.05, n=6). This negative correlation
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was not observed in animals fed the KD (r=+0.44, p=n.s., n=10). Midbrain samples from control
and KD animals showed similar results (CD: r=-0.81, p=0.09; KD: r=+0.41, p=n.s.). No other
brain regions showed this type of relationship. Interactions between adenosine and the DAergic
system are well documented (Ferre et al., 1991; Ferré et al., 1991; Pinna et al., 1996; Ginés et al.,
2000; Salim et al., 2000; Short et al., 2006). Krügel et al. (Krügel et al., 2003) reported that
perfusion of adenosine into the nucleus accumbens significantly reduced extracellular DA
concentration and suggests that stimulation of A1 receptors facilitates this decrease. Both the
DAergic and adenosinergic systems have been implicated in the modulation of seizures (Fedele
et al., 2006; Bozzi and Borrelli, 2013). The negative correlation between adenosine and DA
activity is consistent with an inhibitory modulation by adenosine. Inhibitory A1 receptors (A1R)
are heavily expressed in the cortex (Rivkees et al., 1995). While it is not clear if the present
findings represent a loss of inhibitory modulation, a putative mechanism could be as follows: (a)
the KD produced increased release of ATP with resultant increased extracellular adenosine
levels; (b) this increase in extracellular adenosine could alter the modulatory effect on DA cells
from one of A1R-dependent inhibition to one of excitation by presynaptic A2A receptors; (c)
increased A2A receptor stimulation would result in increased DAergic activity (Okada et al.,
1996; Quarta et al., 2004); (d) the increased DAergic activity may then act on cortical
glutamatergic neurons impacting seizure activity. De Sarro et al. (De Sarro et al., 1999) reported
seizure suppression in an animal model of reflex epilepsy by A2A agonists. Furthermore, the
results of a recently published study indicate that selective antagonism of A1Rs and A2ARs
reverses the anticonvulsant effect of caprylic acid in mice (Socała et al., 2015).
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Control

DOPAC+HVA/DA

8

KD

6
4
2
0
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Adenosine (ug/mg protein)
a

Figure 2. The correlation between cortical tissue adenosine levels and DA activity as measured by the sum of DA
metabolites (DOPAC and HVA) divided by DA levels. Correlation coefficients (r) were -0.88 (p<0.05, n=6) and
+0.44 (p=n.s., n=10) for control and KD, respectively. Values from motor and somatosensory cortices were
combined for each diet group.
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DA activity values taken from ref. 3

To our knowledge, the current paper is the first to evaluate the effect of a chronic KD on
tissue levels of purines in multiple brain regions of experimental animals. Figure 3 is a graphical
representation of adenosine tissue content in the brain structures analyzed. Interestingly,
adenosine levels varied in a descending manner in both diet groups from anterior to posterior
ranging from 61.1 µg/mg protein in the motor cortex to 18.5 µg/mg protein in the midbrain. A
recent paper measuring cerebral adenosine levels in five strains of mice using HPLC reported
wide variability across five inbred mouse strains (Pani et al., 2014). For example, in the cerebral
cortex the strain with the highest adenosine levels was 415% greater than the strain with the
lowest adenosine levels. The present paper reports cortical adenosine levels at 71.8µg/mg
protein compared to 0.013µg/mg wet weight reported by Pani and his colleagues. One possible
explanation for could be that the samples used in the current study had previously been used in
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another and may have been thawed and frozen multiple times allowing for possible breakdown
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of upstream adenosine metabolites.

Brain Region
Figure 3. Adenosine levels in various structures of mouse brain were evaluated in eight week-old mice fed either a
ketogenic diet or control diet for three weeks. No significant differences in adenosine levels were detected; (p>0.05).
Brain structures: MC = motor cortex, SC = somatosensory cortex, NA = nucleus accumbens, ACP = anterior
caudate putamen, PCP = posterior caudate putamen, MB = midbrain.

4. Conclusion
While the current results suggest that the KD does not chronically alter the endogenous
levels of adenosine in brain tissue, they provide valuable insight as to the potential interactions
between the DAergic and purinergic systems and their role in the anti-epileptic effects of the KD.
Further study aims to determine whether extracellular purine levels specifically are affected by
the KD in order to more directly elucidate the role of adenosine in the diet’s efficacy.
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